A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sit

Trial Details

NCT ID
NCT07024784
Phase
PHASE2
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • IMGN151
  • Carboplatin
  • Bevacizumab
  • Olaparib
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Teaneck, New Jersey, United States|40.8976,-74.01597
  • Syracuse, New York, United States|43.04812,-76.14742

Key Eligibility Criteria

  • ECOG performance status of 0 or 1
  • Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression …
  • Participants will have high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC).
  • Participant has completed prior therapy within the specified times below:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →